Abbott Joins Race To Develop Nerve Growth Factor Antibody With PanGenetics Deal
This article was originally published in The Pink Sheet Daily
Abbott will pay PanGenetics $170 million upfront for the Phase I antibody. Pfizer, Johnson & Johnson and Sanofi-Aventis are among the firms with NGF antibodies in development.
You may also be interested in...
New company Tolero helps MannKind de-risk a preclinical BTK inhibitor program in a “double-jointed” deal in which the “bio-bucks” eventually could flow in either direction.
FDA sets March 12 as date for the Arthritis Advisory Committee to weigh in on whether safety issues are a barrier to development of anti-NGF compounds as analgesics. Developers’ trials are on hold while FDA considers the potential for adverse effects seen in osteoarthritis patients taking the monoclonal antibodies for pain.
Abbott Biotech Ventures is the lead investor in a Series B fundraising for Creabilis to move its psoriasis candidate through Phase II.